iTeos Therapeutics, Inc.

ITOS · NASDAQ
Analyze with AI
6/30/2025
3/31/2025
12/31/2024
9/30/2024
Revenue$0$0$0$0
% Growth
Cost of Goods Sold$0$324$0$302
Gross Profit$0-$324-$34,388-$302
% Margin
R&D Expenses$57,275$29,039$37,523$36,686
G&A Expenses$10,181$10,982$11,809$12,112
SG&A Expenses$10,181$10,982$11,809$12,112
Sales & Mktg Exp.$0$0$0$0
Other Operating Expenses$16,335$0$0$0
Operating Expenses$83,791$40,021$49,332$48,798
Operating Income-$83,791-$40,021-$49,332-$48,798
% Margin
Other Income/Exp. Net$6,732$6,508$12,975$5,683
Pre-Tax Income-$77,059-$33,513-$36,357-$43,115
Tax Expense$1,670$607$7,355$2,243
Net Income-$78,729-$34,613-$43,712-$45,358
% Margin
EPS-1.81-0.8-1.08-1.05
% Growth-126.3%25.9%-2.9%
EPS Diluted-1.81-0.8-1.08-1.05
Weighted Avg Shares Out43,56543,24140,47443,135
Weighted Avg Shares Out Dil43,56543,24140,47443,135
Supplemental Information
Interest Income$6,382$6,950$7,659$8,010
Interest Expense$0$0$0$0
Depreciation & Amortization$340$324$322$302
EBITDA-$66,181-$33,682-$47,777-$47,693
% Margin
iTeos Therapeutics, Inc. (ITOS) Financial Statements & Key Stats | AlphaPilot